These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31318977)

  • 21. PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance.
    Lokman U; Erickson AM; Vasarainen H; Rannikko AS; Mirtti T
    Eur Urol Focus; 2018 Dec; 4(6):867-873. PubMed ID: 28753869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.
    Huang KC; Bégin LR; Palanisamy N; Donnelly B; Bismar TA
    Urol Oncol; 2016 May; 34(5):235.e1-10. PubMed ID: 26725250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.
    Gumuskaya B; Gurel B; Fedor H; Tan HL; Weier CA; Hicks JL; Haffner MC; Lotan TL; De Marzo AM
    Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):209-15. PubMed ID: 23545904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PTEN, ERG, SPINK1, and TFF3 Status and Relationship in a Prostate Cancer Cohort from Jordanian Arab Population.
    Al Bashir S; Alorjani MS; Kheirallah K; Al Hamad M; Haddad HK; Al-Dwairy A; Bani-Fawwaz BA; Aldaoud N; Halalsheh O; Amawi S; Matalka II
    Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256434
    [No Abstract]   [Full Text] [Related]  

  • 25. Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.
    Lahdensuo K; Erickson A; Saarinen I; Seikkula H; Lundin J; Lundin M; Nordling S; Bützow A; Vasarainen H; Boström PJ; Taimen P; Rannikko A; Mirtti T
    Mod Pathol; 2016 Dec; 29(12):1565-1574. PubMed ID: 27562498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone.
    Liu S; Yoshimoto M; Trpkov K; Duan Q; Firszt M; Corcos J; Squire JA; Bismar TA
    Cancer Biol Ther; 2011 Mar; 11(6):562-6. PubMed ID: 21178509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
    Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
    Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification.
    Bismar TA; Hegazy S; Feng Z; Yu D; Donnelly B; Palanisamy N; Trock BJ
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2117-2125. PubMed ID: 30101374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.
    Reid AH; Attard G; Ambroisine L; Fisher G; Kovacs G; Brewer D; Clark J; Flohr P; Edwards S; Berney DM; Foster CS; Fletcher A; Gerald WL; Møller H; Reuter VE; Scardino PT; Cuzick J; de Bono JS; Cooper CS;
    Br J Cancer; 2010 Feb; 102(4):678-84. PubMed ID: 20104229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.
    Bismar TA; Yoshimoto M; Duan Q; Liu S; Sircar K; Squire JA
    Histopathology; 2012 Mar; 60(4):645-52. PubMed ID: 22260502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Haney NM; Faisal FA; Lu J; Guedes LB; Reuter VE; Scher HI; Eastham JA; Marchionni L; Joshu C; Gopalan A; Lotan TL
    J Urol; 2020 Feb; 203(2):344-350. PubMed ID: 31502941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.
    Pust A; Kylies D; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Salomon G; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Krech T; Schlomm T; Melling N
    Hum Pathol; 2016 Feb; 48():102-10. PubMed ID: 26614400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.
    Han B; Mehra R; Lonigro RJ; Wang L; Suleman K; Menon A; Palanisamy N; Tomlins SA; Chinnaiyan AM; Shah RB
    Mod Pathol; 2009 Aug; 22(8):1083-93. PubMed ID: 19407851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
    Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
    Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression profile of MAGI2 gene as a novel biomarker in combination with major deregulated genes in prostate cancer.
    Mahdian R; Nodouzi V; Asgari M; Rezaie M; Alizadeh J; Yousefi B; Shahrokh H; Abolhasani M; Nowroozi M
    Mol Biol Rep; 2014 Sep; 41(9):6125-31. PubMed ID: 24985972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status.
    Geybels MS; McCloskey KD; Mills IG; Stanford JL
    Prostate; 2017 Feb; 77(3):282-290. PubMed ID: 27753122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The association of Phosphatase and tensin homolog (PTEN) deletion and prostate cancer risk: A meta-analysis.
    Gao T; Mei Y; Sun H; Nie Z; Liu X; Wang S
    Biomed Pharmacother; 2016 Oct; 83():114-121. PubMed ID: 27470558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Associations of PTEN and ERG with Magnetic Resonance Imaging Visibility and Assessment of Non-organ-confined Pathology and Biochemical Recurrence After Radical Prostatectomy.
    Eineluoto JT; Sandeman K; Pohjonen J; Sopyllo K; Nordling S; Stürenberg C; Malén A; Kilpeläinen TP; Santti H; Petas A; Matikainen M; Pellinen T; Järvinen P; Kenttämies A; Rannikko A; Mirtti T
    Eur Urol Focus; 2021 Nov; 7(6):1316-1323. PubMed ID: 32620540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.